The development of an in-house capability to simulate arterial and venous blood parameters represents a significant technological advancement for Inspira Technologies. This capability could reduce the time and cost associated with R&D by eliminating the need for in vivo animal testing. It positions the company to potentially introduce new medical technologies more quickly and efficiently, which could positively impact its stock price in the short term.